CoChat

Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck

Open access
Huang, Kie Kyon, Jang, Kang Won, Kim, Sangwoo, Kim, Han Sang, Kim, Sung-Moo, Kwon, Hyeong Ju, Kim, Hye Ryun, Yun, Hwan Jung, Ahn, Myung Ju, Park, Keon Uk, Ramnarayanan, Kalpana, McPherson, John R., Zhang, Shenli, Rhee, Je-Keun, Vettore, André L., Das, Kakoli, Ishimoto, Takatsugu, Kim, Joo Hang, Koh, Yoon Woo, Kim, Se Hun, Choi, Eun Chang, Teh, Bin Tean, Rozen, Steven G., Kim, Tae-Min, Tan, Patrick, Cho, Byoung Chul · 2016 · Scientific Reports
Cited by 25

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Dacomitinib, an irreversible pan-HER inhibitor, had shown modest clinical activity in squamous cell carcinoma of head and neck (SCCHN) patients. Therefore, validated predictive biomarkers are required to identify patients most likely to benefit from this therapeutic option. To characterize the genetic landscape of cisplatin-treated SCCHN genomes and identify potential predictive biomarkers for dacomitinib sensitivity, we performed whole exome sequencing on 18 cisplatin-resistant metastatic SCCHN tumors and their matched germline DNA. Platinum-based chemotherapy elevated the mutation rates of SCCHN compared to chemotherapy-naïve SCCHNs. Cisplatin-treated SCCHN genomes uniquely exhibited a novel mutational signature characterized by C:G to A:T transversions at C C R sequence contexts that may have arisen due to error-prone translesional synthesis. Somatic mutations in REV3L, the gene encoding the catalytic subunit of DNA polymerase ζ involved in translesional synthesis, are significantly enriched in a subset of patients who derived extended clinical benefit to dacomitinib (P = 0.04). Functional assays showed that loss-of-function of REV3L dramatically enhanced the sensitivity of SCCHN cells to dacomitinib by the loss of both translesion synthesis and homologous recombination pathways. Our data suggest that the ‘platinum’ mutational signature and inactivation of REV3L may inform treatment options in patients of recurrent SCCHN.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep19552

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 25

Metadata

Authors
Huang, K. K., Jang, K. W., Kim, S., Kim, H. S., Kim, S.-M., Kwon, H. J., Kim, H. R., Yun, H. J., Ahn, M. J., Park, K. U., Ramnarayanan, K., McPherson, J. R., Zhang, S., Rhee, J.-K., Vettore, A. L., Das, K., Ishimoto, T., Kim, J. H., Koh, Y. W., Kim, S. H., Choi, E. C., Teh, B. T., Rozen, S. G., Kim, T.-M., Tan, P., & Cho, B. C.
Venue
Scientific Reports
Published
2016-01-21
Volume
6
Issue
1
Pages
19552-19552
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2254305923
Cited by
25
References
1
FWCI
4.09
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck. https://app.cochat.ai/papers/10.1038/srep19552
The paper
Huang, K. K., Jang, K. W., Kim, S., Kim, H. S., Kim, S.-M., Kwon, H. J., Kim, H. R., Yun, H. J., Ahn, M. J., Park, K. U., Ramnarayanan, K., McPherson, J. R., Zhang, S., Rhee, J.-K., Vettore, A. L., Das, K., Ishimoto, T., Kim, J. H., Koh, Y. W., . . . Cho, B. C. (2016). Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck. Scientific Reports. https://doi.org/10.1038/srep19552

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.